clinical trial · NCT07881458
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company·phase3·not yet recruiting·n = 1,000
ObesityOverweightDiabetes Mellitus, Type 2eloralintide and tirzepatideTirzepatide
brief summary
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.
started
Nov 1, 2026
primary completion
Oct 1, 2029
completion
Nov 1, 2029
last updated
Oct 19, 2026
official title
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol